Phase 3 Ovarian Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with a specific type of ovarian cancer (high-grade serous or endometrioid), including cancer that started in the peritoneum or fallopian tubes, confirmed by a laboratory tissue test.
- People whose cancer came back or got worse after receiving their first course of platinum-based chemotherapy (carboplatin and paclitaxel, at least 4 cycles), with or without a drug called bevacizumab, and whose cancer returned at least 6 months after their last platinum-based treatment.
- People with a BRCA gene mutation or a condition called HRD-positive disease must have previously received a type of maintenance therapy called a PARP inhibitor (alone or with bevacizumab).
- People who have areas of cancer that can be measured on a scan at the start of the trial.
- People who are able to provide a tissue sample from their tumour.
- People who are in reasonably good general health, as measured by a standard medical scoring system (a score of 0 or 1 on the ECOG scale, meaning fully active or able to carry out light activity).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian cancer is of a specific tissue type, including clear cell, mucinous, or sarcomatous, mixed tumours containing any of these types, or low-grade/borderline ovarian tumours.
- People who have previously been treated with anti-blood vessel growth drugs other than bevacizumab or an approved copy of bevacizumab (biosimilar).
- People who have previously received a type of targeted drug treatment (called an antibody-drug conjugate) that contains a topoisomerase-1 inhibitor.
- People who have previously received a type of targeted drug treatment (antibody-drug conjugate) that targets a protein called folate receptor alpha (FRα).
- Other criteria set out in the trial protocol may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Official, Genmab
Phone: +4570202728
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.